Table of Content

Open Access iconOpen Access

ARTICLE

Use of vasoactive agents in postoperative pediatric cardiac patients: Insights from a national database

by

1 Division of Pediatric Cardiology, Chicago Medical School, Advocate Children’s Hospital, Chicago, Illinois
2 Division of Pediatric Cardiology, Baylor College of Medicine, Texas Children’s Hospital, Houston, Texas

* Corresponding Author: Rohit S. Loomba, Division of pediatric cardiology, Chicago Medical School, Advocate Children’s Hospital, 4440 95th street, Chicago, IL, 60453. Email: email

Congenital Heart Disease 2019, 14(6), 1176-1184. https://doi.org/10.1111/chd.12837

Abstract

Objective: The main goal of this study is to examine the variation in vasoactive agent prescription patterns across a large cohort of patients. In addition, we sought to determine the association between the number of vasoactive agents used during admissions and characteristics of admissions utilizing varying numbers of vasoactive agents.
Methods: This was a multi-institutional, cross-sectional study of the pediatric health information system database of patients who underwent congenital heart surgery and received vasoactive agents from 2004 to 2015. The international classification of disease-9 (ICD-9) codes were used to select admissions to those only pertaining to cardiac patients. The vasoactive agents investigated included epinephrine, norepinephrine, dopamine, dobutamine, milrinone, and vasopressin.
Results: A total of 43 441 postoperative pediatric cardiac admissions were identified and included in the final analyses. Of these, a majority used at least one vasoactive agent at some point during the admissions with the median being three vasoactives. Each vasoactive was utilized with decreasing frequency throughout the study period except for vasopressin which increased in frequency of use. After adjusting for multiple confounding factors, only milrinone was associated with decreased inpatient mortality in any postoperative subset, while the rest of the vasoactive were associated with increased inpatient mortality in some of the postoperative subsets.
Conclusion: Vasoactive agents have decreased in frequency of use in postoperative pediatric cardiac admissions, except for vasopressin. Only milrinone was found to be associated with decreased inpatient mortality in any subset of these patients, while all other vasoactive agents were found to be associated with increased inpatient mortality at least in one of the subsets.

Keywords


Cite This Article

APA Style
Loomba, R.S., Flores, S. (2019). Use of vasoactive agents in postoperative pediatric cardiac patients: insights from a national database. Congenital Heart Disease, 14(6), 1176-1184. https://doi.org/10.1111/chd.12837
Vancouver Style
Loomba RS, Flores S. Use of vasoactive agents in postoperative pediatric cardiac patients: insights from a national database. Congeni Heart Dis. 2019;14(6):1176-1184 https://doi.org/10.1111/chd.12837
IEEE Style
R.S. Loomba and S. Flores, “Use of vasoactive agents in postoperative pediatric cardiac patients: Insights from a national database,” Congeni. Heart Dis., vol. 14, no. 6, pp. 1176-1184, 2019. https://doi.org/10.1111/chd.12837



cc Copyright © 2019 The Author(s). Published by Tech Science Press.
This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 1580

    View

  • 1071

    Download

  • 0

    Like

Share Link